Journal News

Innovative platform empowers scientists to transform venoms into therapeutics

Andrea Lius
May 13, 2025

Some of the most successful and effective drugs, like Ozempic, come from animal venoms. However, scientists usually only discover the therapeutic potential of venoms by chance. Recently, an international group of researchers, led by Meng-Hsuan Hsiao of Ben Larman ’s laboratory at Johns Hopkins University, set out to change that by developing a workflow to accelerate drug discovery from peptides, or short sequences of amino acids, with sequences and structures that resemble animal venoms. They published their study in Molecular & Cellular Proteomics.

Simplified diagram of Meng-Hsuan Hsiao of Ben Larman’s platform to facilitate drug discovery from animal venoms using M13 hyperphages.
Ben Larman
Simplified diagram of Meng-Hsuan Hsiao of Ben Larman’s platform to facilitate drug discovery from animal venoms using M13 hyperphages.

Hsiao and colleagues demonstrated that their platform could evaluate over 10,000 venom-like peptides’ ability to bind specific receptors on human cells. Larman’s group teamed up with Martin Steinegger, an assistant professor at Seoul National University, who built a “metavenome library” from known animal venom sequences and additional peptides based on sequence homology.

“A library allows us to explore a much larger space of possible lead compounds for drugs,” Larman said. “You don’t even need to have a starting hypothesis.”

The researchers expressed peptides from this library on the surface of bacteriophages, or bacteria-infecting viruses, a technique also known as phage display. For their platform, Larman’s team used what he called a specific “flavor” of phage: the M13 hyperphage.

Hyperphages carry genetic mutations that make them display five copies of venom-like peptides on their surface. Therefore, the displayed peptides could interact with multiple receptors, amplifying the signal and allowing the researchers to detect weaker interactions.

“The way we used hyperphages to display venoms has never been done before,” said Larman.

Unlike other phages, M13 phages are secreted through the bacterial periplasm, the space between the bacteria’s inner and outer cell membranes. The periplasm has an oxidizing chemical environment, Larman explained, and this helps preserve the venom peptides’ disulfide bonds, which are critical for their 3D structures. These disulfide bonds make venoms attractive therapeutics because they are highly compact and resistant to degradation.

Using their platform, Larman’s team identified six proteins in the metavenome library that bind and activate the human itch receptor MAS-related G protein-coupled receptor X4, or MRGPRX4. They found that these proteins share a unique folding pattern called the Kunitz domain, which is commonly known to inhibit serine protease activity. In the future, Larman’s team plans to expand their metavenome library to include even more peptides in search of a potent MRGPRX4 antagonist that can be developed into an anti-itch drug.

“I think that if you can find an agonist, you can also find an antagonist,” Larman said, “And we can likely achieve this by expanding our library.”

Larman said he hopes to integrate generative artificial intelligence into their system to broaden the library to include novel venom-like peptides.

“Once set up and integrated,” he said. “I can see this cycle of computational prediction and experimental validation being really powerful in drug discovery.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Andrea Lius

Andrea Lius is a Ph.D. candidate in the Ong quantitative biology lab at the University of Washington. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
Feature

Using 'nature’s mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
News

Cracking cancer’s code through functional connections

July 2, 2025

A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
In-person Conference

Gaze into the proteomics crystal ball

July 1, 2025

The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17–21 in Cambridge, Massachusetts.

Bacterial enzyme catalyzes body odor compound formation
Journal News

Bacterial enzyme catalyzes body odor compound formation

June 27, 2025

Researchers identify a skin-resident Staphylococcus hominis dipeptidase involved in creating sulfur-containing secretions. Read more about this recent Journal of Biological Chemistry paper.

Neurobiology of stress and substance use
Profile

Neurobiology of stress and substance use

June 19, 2025

MOSAIC scholar and proud Latino, Bryan Cruz of Scripps Research Institute studies the neurochemical origins of PTSD-related alcohol use using a multidisciplinary approach.